AR050626A1 - Composicion quimica y metodo para tratar desorden gastrointestinal - Google Patents

Composicion quimica y metodo para tratar desorden gastrointestinal

Info

Publication number
AR050626A1
AR050626A1 ARP050103687A ARP050103687A AR050626A1 AR 050626 A1 AR050626 A1 AR 050626A1 AR P050103687 A ARP050103687 A AR P050103687A AR P050103687 A ARP050103687 A AR P050103687A AR 050626 A1 AR050626 A1 AR 050626A1
Authority
AR
Argentina
Prior art keywords
chemical composition
gastrointestinal disorder
treat gastrointestinal
effective
subject
Prior art date
Application number
ARP050103687A
Other languages
English (en)
Spanish (es)
Inventor
Ryohei Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050626(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR050626A1 publication Critical patent/AR050626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ARP050103687A 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal AR050626A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
AR050626A1 true AR050626A1 (es) 2006-11-08

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103687A AR050626A1 (es) 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal

Country Status (16)

Country Link
US (2) US8748481B2 (enExample)
EP (1) EP1791545B1 (enExample)
JP (4) JP2008511541A (enExample)
KR (4) KR20180033310A (enExample)
CN (1) CN102885821A (enExample)
AR (1) AR050626A1 (enExample)
AU (1) AU2005278323B2 (enExample)
BR (1) BRPI0514891A (enExample)
CA (1) CA2577284A1 (enExample)
ES (1) ES2603381T3 (enExample)
IL (1) IL181332A (enExample)
MX (1) MX2007002602A (enExample)
NO (1) NO340989B1 (enExample)
NZ (1) NZ553434A (enExample)
TW (1) TWI387454B (enExample)
WO (1) WO2006025599A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
EP2682130A1 (en) * 2006-01-24 2014-01-08 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN104379140A (zh) * 2012-04-23 2015-02-25 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
EP2952206B1 (en) * 2013-02-04 2018-10-24 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
PT1220849E (pt) 1999-10-15 2004-10-29 Sucampo Ag Composicao de compostos biciclicos e metodo para a sua estabilizacao
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
JP4597481B2 (ja) 2001-05-18 2010-12-15 スキャンポ・アーゲー 下剤組成物
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ541110A (en) * 2002-12-27 2008-11-28 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
WO2005002588A1 (en) 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Also Published As

Publication number Publication date
NO340989B1 (no) 2017-07-31
AU2005278323A1 (en) 2006-03-09
KR20170003712A (ko) 2017-01-09
US20140315994A1 (en) 2014-10-23
IL181332A0 (en) 2007-07-04
JP2008511541A (ja) 2008-04-17
CN102885821A (zh) 2013-01-23
NZ553434A (en) 2010-01-29
TWI387454B (zh) 2013-03-01
AU2005278323B2 (en) 2011-03-17
JP2013049688A (ja) 2013-03-14
US8748481B2 (en) 2014-06-10
JP2018150354A (ja) 2018-09-27
CA2577284A1 (en) 2006-03-09
IL181332A (en) 2015-09-24
WO2006025599A1 (en) 2006-03-09
MX2007002602A (es) 2007-04-25
JP6408426B2 (ja) 2018-10-17
KR20180033310A (ko) 2018-04-02
NO20071704L (no) 2007-05-31
JP2015166377A (ja) 2015-09-24
ES2603381T3 (es) 2017-02-27
KR20140019006A (ko) 2014-02-13
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
TW200612901A (en) 2006-05-01
BRPI0514891A (pt) 2008-06-24
EP1791545A1 (en) 2007-06-06
EP1791545B1 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY32032A (es) "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas"
CL2024002764A1 (es) Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
AR049844A1 (es) Memantina como tratamiento adyuvante con antipsicoticos atipicos en pacientes con esquizofrenia
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
AR050626A1 (es) Composicion quimica y metodo para tratar desorden gastrointestinal
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AR124479A1 (es) Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
ES2491565T3 (es) Agente de transfección
AR107905A2 (es) Composición química y método para tratar desorden gastrointestinal
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)

Legal Events

Date Code Title Description
FC Refusal